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Little information exists on the effect of race and ethnicity on collection of peripheral blood stem cells (PBSC) for
allogeneic transplantation. We studied 10,776 donors from the National Marrow Donor Program who under-
went PBSC collection from 2006 to 2012. Self-reported donor race/ethnic information included Caucasian,
Hispanic, Black/African American (AA), Asian/Paciﬁc Islander (API), and Native American (NA). All donors were
mobilized with subcutaneous ﬁlgrastim at an approximate dose of 10 mg/kg/day for 5 days. Overall, AA donors
had the highest median yields of mononuclear cells per liter and CD34þ cells per liter of blood processed
(3.1  109 and 44  106, respectively), whereas Caucasians had the lowest median yields at 2.8  109 and
33.7  106, respectively. Multivariate analysis of CD34þ per liter mobilization yields using Caucasians as the
comparator and controlling for age, gender, body mass index, and year of apheresis revealed increased yields in
overweight and obese AA and API donors. In Hispanic donors, only male obese donors had higher CD34þ per
liter mobilization yields compared with Caucasian donors. No differences in CD34þ per liter yields were seen
between Caucasian and NA donors. Characterization of these differences may allow optimization of mobiliza-
tion regimens to allow enhancement of mobilization yields without compromising donor safety.
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Mobilizedperipheralbloodstemcells (PBSC)are commonly
used in allogeneic hematopoietic cell transplantation because
of the relative ease of collection and rapid engraftment [1,2].
However, there is signiﬁcantvariation inmobilization response
to ﬁlgrastim (granulocyte colonyestimulating factor, G-CSF) in
healthy donors, which sometimes requires additional apher-
esis collections or repeat mobilization cycles to collect an
adequate PBSC dose for transplantation [3,4]. Information on
the effect of various donor demographic, laboratory, and other
factors onboth peakCD34þ responses and apheresis cell yields
in both the related and unrelated settings is inconsistent [5-7].
Racial variations have been described in the baseline cell
counts, which may have an effect on the ability to adequately
collect stem cells [8]. Little information exists on the effect of
donor race and ethnicity on mobilization, especially in the
unrelated donor setting [9-11]. This studyanalyzes the effect of
donor race and ethnicityonPBSCmobilization in a large cohort
of adult unrelated donors.
METHODS
Data Sources
The Center for International Blood and Marrow Transplant Research
(CIBMTR) is a combined research program of the Medical College of Wis-
consin and the National Marrow Donor Program (NMDP). CIBMTR com-
prises a voluntary network of more than 450 transplantation centers
worldwide that contribute detailed data on consecutive allogeneic and
autologous transplantations to a centralized statistical center. Observational
studies conducted by the CIBMTR are performed in compliance with all
applicable federal regulations pertaining to the protection of human
research participants. Protected health information used in the performance
of such research is collected andmaintained in CIBMTR’s capacity as a Public
Health Authority under the Health Insurance Portability and Accountability
Act of 1996 Privacy Rule. Additional details regarding the data source are
described elsewhere [12].
Study Population
The study population consisted of United States’ volunteer donors from
the NMDP who underwent G-CSFe(ﬁlgastrim, Neupogen, Amgen, Thou-
sand Oaks, CA) mobilized PBSC collection from January 2006 to December
2012. Only ﬁrst-time hematopoietic progenitor cell (HPC) donors for whom
data were available from baseline to the ﬁrst day of apheresis on the NMDP
data collection forms were included. Donor race/ethnicity was self-reported.
Donors were classiﬁed as Caucasian, Hispanic/Latino (Hispanic), Black/
African American (AA), Asian/Paciﬁc Islander (API), or Native American (NA).
Donors who were of other/multiple/unknown race were excluded from the
analysis. Only donors from apheresis centers that collected from both
Caucasian and minority donors were included. We identiﬁed 10,776
volunteer donors eligible for inclusion in this study. All donors provided
written informed consent for participation in research studies approved by
the NMDP institutional review board and were evaluated for medical suit-
ability, transplantation-transmissible infectious diseases, and contraindica-
tions for PBSC donation using standardized NMDP criteria.
PBSC Donation and Data Collection
The PBSC donation processes were facilitated by 63 donor centers and
89 apheresis centers. Donor centers manage donor medical evaluations,
infectious disease marker testing, and G-CSF administration. They are also
responsible for coordinating the donation process, monitoring the donor’s
recovery, and data reporting. Apheresis centers perform PBSC collections,
coordinate donor G-CSF administration in conjunction with local donor
centers as needed, assist donor centers with data reporting, and are
responsible for submitting PBSC Product Analysis Forms to the NMDP.
All PBSC mobilizations were performed according to the NMDP-
sponsored and institutional review boardeapproved research protocol for
manufacturing PBSC products, operated under an Investigational New Drug
application with the United States Food and Drug Administration. Dosing of
G-CSF for volunteer donors was approximately 10 mg/kg/day actual body
weight rounded to combinations of 300 mg and 480 mg vials based on the
donor’s actual body weight, as long as protocol deﬁned targets of 13.3 mg/kg
or less per day were not exceeded. This was done for ease of administration
of G-CSF. The protocol included provisions for G-CSF dose reductions in the
presence of high-grade symptoms. Typically, donors received subcutaneous
G-CSF daily for 4 days before and on the ﬁrst day of apheresis. All donorsunderwent 1 or 2 days of apheresis; however, only apheresis products
collected on the ﬁrst day were analyzed. The volume of whole blood pro-
cessed was targeted to be between 12 and 24 L per collection, depending on
recipient weight and/or immediate preprocedure donor blood CD34þ cell
count. The protocol allowed the maximum total blood volume processed to
be 24 L, whether collected over 1 or 2 days. If the PBSC product could not be
collected using peripheral veins, a central venous catheter (CVC) was used.
Data collection began at the time of the donor’s medical evaluation to
determine suitability to donate HPCs, and continued through each day of G-
CSF, on the day of each apheresis procedure, and after collection.
Endpoints and Statistical Analysis
The primary endpoint of this study was the number of mononuclear
cells (MNC) and CD34þ cells collected after 1 day of apheresis. Secondary
endpoints included change of white blood cells (DWBC), MNC (DMNC),
neutrophil (DNeu), and platelet (DPlt) counts from baseline before the start
of G-CSF to after G-CSF, before the start of apheresis. Signiﬁcant variability
exists among apheresis centers concerning number of days of collection and
volume of blood processed per day. To avoid variability inherent in the
second day of collection, we normalized the MNC and CD34þ cell counts to
volume of blood processed on the ﬁrst day of apheresis.
The main parameter analyzed is the self-reported race/ethnicity of the
donor, classiﬁed as Caucasian, Hispanic/Latino, AA, API, or NA. The analysis
quantiﬁed other donor and collection characteristics by race/ethnicity. These
variables included donor gender, age, weight, body mass index (BMI), base-
line complete blood count (CBC), total G-CSF dose per kilogram donor actual
body weight, year of donation, presence/absence of a CVC, and apheresis
center. Univariate comparisons of these factors between the 5 racial/ethnic
groupswereperformedusing the chi-square test for categorical variables and
the Kruskal-Wallis test for continuous variables. Linear mixed model with a
random effect for apheresis center was used to analyze the effect of donor
race/ethnicity on the primary and secondary endpoints. Interactions be-
tween themain effect and all other signiﬁcant factorswere checked. Because
a number of pairwise comparisonswere required,we considered a difference
of P < .005 as signiﬁcant using a Bonferroni correction.
RESULTS
Donor Demographics
A total of 10776 unrelated volunteer PBSC donors were
available for analysis. The baseline characteristics of the
various racial/ethnic groups are shown in Table 1. The ma-
jority of donors were Caucasians (79.4%). Hispanics
composed the second largest group at 9.4%, followed by API
(5.5%), AA (4.7%), and NA (1.1%). NA donors were generally
the oldest donors (median age, 38 years), whereas API do-
nors were the youngest (median age, 32 years). Interestingly,
the majority of donors in all racial/ethnic groups were either
overweight or obese (as deﬁned in Table 1). Percentages
varied from 50% in API, 67% in Caucasians, to 80% in AA.
Although Hispanic and AA donors were more likely to be
obese (Table 1), stratiﬁcation of the various races/ethnicities
by BMI found Caucasians were the heaviest donors in all BMI
categories, whereas API were the lightest in the normal and
obese groups and Hispanics were the lightest in the over-
weight group (Table 2). There were signiﬁcantly more male
donors in the Caucasian, API, and NA groups, whereas male
to female ratios in the Hispanic and AA groups were roughly
equal. There was a statistically signiﬁcant difference in use of
CVCs, with AA having the highest percentage of insertion
(19%) and Caucasians having the lowest (8%, P < .001).
Response to G-CSF
Baseline counts are shown in Table 1 and donor responses
to G-CSF are seen in Table 3. In summary, AA donors had the
lowest median baseline WBC and neutrophil counts,
whereas NA donors had the highest baseline WBC counts.
After 5 days of G-CSF stimulation, however, AA donors had
the largest DWBC (median, 38.7  109/L; range 6.1 to 79.3),
DNeu (median, 33.6  109/L; range 5.6 to 68.1), and DMNC
(median, 4.5109/L; range,.7 to 16.8) after 5 days of G-CSF
stimulation, whereas Caucasians had the smallest DWBC
Table 1
Characteristics of Unrelated PBSC Donors Facilitated by the NMDP, 2006-2012
Variable Caucasian HIS AA API NA P Value
No. donors 8560 1010 504 587 115
Male/female 5601/2959 (65/35) 508/502 (50/50) 244/260 (48/52) 367/220 (63/37) 68/47 (59/41) <.001
Donor age at donation <.001
18 to 29 3434 (40) 368 (36) 149 (30) 230 (39) 37 (32)
30 to 39 2348 (28) 309 (31) 172 (34) 226 (39) 31 (27)
40 to 49 1890 (22) 241 (24) 123 (24) 96 (16) 29 (25)
50 to 61 888 (10) 92 (9) 60 (12) 35 (6) 18 (16)
Median (range) 34 (18-61) 35 (18-61) 36 (19-60) 32 (19-60) 38 (20-60) <.001
Donor BMI (kg/m2) <.001
Underweight (<18.5) 50 (1) 8 (1) 3 (1) 10 (2) 0
Normal (18.5-24.9) 2753 (32) 237 (23) 87 (17) 285 (49) 24 (21)
Overweight (25-29.9) 3346 (39) 376 (37) 184 (37) 204 (35) 39 (34)
Obese (30þ) 2408 (28) 388 (38) 230 (46) 88 (15) 52 (45)
Unknown 3 (N/A) 1 (N/A) 0 (N/A) 0 (N/A) 0 (N/A)
Median (range) 27.0 (15.7-61.3) 28.4 (17.0-49.5) 29.5 (16.7-50.6) 25.0 (16.4-43.5) 29.4 (19.0-44.0) <.001
Donor weight, median
(range), kg
84 (41-176) 81 (41-160) 86 (42-138) 72 (37-145) 87 (47-154) <.001
Year of donation .022
2006 931 (11) 118 (12) 50 (10) 36 (6) 11 (10)
2007 993 (12) 109 (11) 61 (12) 64 (11) 15 (13)
2008 1120 (13) 137 (14) 67 (13) 81 (14) 24 (21)
2009 1156 (13) 141 (14) 84 (17) 93 (16) 16 (14)
2010 1269 (15) 163 (16) 78 (15) 76 (13) 19 (17)
2011 1405 (16) 159 (16) 80 (16) 106 (18) 10 (9)
2012 1686 (20) 183 (18) 84 (17) 131 (22) 20 (17)
G-CSF dose
5-Day total dose, median
(range), mg
4500 (1800-6720) 4500 (2400-6300) 4500 (2340-6000) 3900 (2400-6240) 4500 (2400-6000) <.001
5-Day total dose/donor
weight, median
(range), mg/kg
52.8 (27.0-93.6) 52.9 (33.6-73.5) 52.5 (26.8-64.1) 54.2 (40.0-73.5) 52.7 (30.5-62.6) <.001
Baseline counts
WBC, median
(range),  109/L
6.3 (.4-18.9) 6.7 (2.5-15.1) 5.6 (2.4-13.2) 6.2 (3.0-14.9) 6.9 (4.0-11.7) <.001
Platelets, median
(range),  109/L
241 (85-585) 257 (112-548) 251 (142-509) 257 (112-474) 245 (145-434) <.001
Neutrophils, median
(range),  109/L
3.9 (.2-14.7) 4.2 (1.3-11.8) 3.1 (1.1-10.7) 3.8 (1.5-11.6) 4.4 (2.2-8.6) <.001
MNC, median
(range),  109/L
2.3 (.2-8.7) 2.5 (.7-5.9) 2.4 (1.1-4.9) 2.3 (1.0-4.6) 2.5 (1.1-4.0) <.001
CVC inserted 725 (8) 136 (13) 98 (19) 61 (10) 10 (9) <.001
Volume of whole blood
processed on collection
day 1, median (range), L
19.1 (2.6-34.6) 18.0 (3.5-32.2) 18.0 (3.7-27.0) 18.0 (2.7-25.7) 18.0 (8.5-24.0) <.001
HIS indicates Hispanic; AA, Black/African American; API, Asian/Paciﬁc Islander; NA, Native American.
Data presented are n (%), unless otherwise indicated.
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27.0  109/L; range, .9 to 91.7), and DMNC (median,
3.4  109/L; range, 2.4 to 28.3).
Cell counts of the apheresis product after 1 day of
collection are shown in Table 4. AA were the most robust
mobilizers, with the highest median CD34þ cells collected
per liter of blood processed at 44.0  106/L (range, .6 to 210),
as well as the highest median total number of CD34þ cells
collected at 704  106 (range, 7.9 to 3985). Conversely, Cau-
casians had the lowest median CD34þ cells collected per liter
at 33.7  106 CD34þ/L (range, .4 to 285), whereas API had the
lowest median total number of CD34þ cells collected at
555.8  106 CD34þ cells (range, 72.4 to 2795). Yield of stem
cells, expressed as percentage of CD34þ cells per MNC, were
the highest in AA donors with a median 1.25% (range, .19 to
16.9). Caucasians and NA were essentially the same, with a
median 1.19% (range, .01 to 43.0) and 1.18% (range, .28 to
6.68), respectively.
Multivariate Analysis
A linear mixed model with a random effect for apheresis
center was used to assess the effect of donor race/ethnicityon collection efﬁciency after adjusting for signiﬁcant effects
among donor gender, age, BMI, and year of donation. For
CD34þ cells collected per liter of blood processed, we found
both gender and BMI had a signiﬁcant interaction with race.
The results between Caucasians versus other racial/ethnic
groups are shown in Figure 1. In general, there was an
increased difference between Caucasians and other donors in
CD34þ cells per liter collected as BMI increased in males. In
female donors, differences in CD34þ cells collected were
variable. Hispanic donors had signiﬁcantly more CD34þ cells
per liter compared with Caucasians, but only among obese
male donors. AA, however, had signiﬁcantly more CD34þ
cells per liter compared with Caucasians among the over-
weight and obese populations in both genders. API donors
had more CD34þ cells per liter compared with Caucasians
only in overweight and obese males. No differences in CD34þ
cells per liter were seen between NA and Caucasian donors.
In comparisons among the 4minority race groups, AA donors
had better collection compared with Hispanic donors (pri-
marily among overweight and obese males), API donors
(primarily among obese males), and NA donors (primarily
among overweight and obese males). A multivariate model,
Table 2
Distribution of Weight in Different BMI Categories According to Race/
Ethnicity
BMI Category Race/
Ethnicity
n Median (kg) Range P Value
Underweight/
normal
Caucasian 2803 68.0 41.0-103.0 <.001
HIS 245 62.0 41.0-93.0
AA 90 66.5 42.0-91.6
API 295 61.0 37.0-92.0
NA 24 66.8 47.0-88.5
Overweight Caucasian 3346 85.0 56.8-123.0 <.001
HIS 376 78.0 52.6-108.0
AA 184 81.7 61.8-112.7
API 204 80.0 56.0-96.0
NA 39 83.6 64.0-96.0
Obese Caucasian 2408 102.1 69.9-175.5 <.001
HIS 388 97.6 68.0-160.1
AA 230 99.6 67.6-138.0
API 88 92.8 72.1-145.5
NA 52 100.3 73.2-154.2
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BMI, age, gender, and year of apheresis, found statistically
signiﬁcant effect of CVC placement on collection yields. The
placement of CVC was associated with a mean reduction in
CD34þ cell yields of 1.91  106/L (P ¼ .003). No signiﬁcant
interactions were seen between CVC placement and race/
ethnicity, which implies that the effect of CVC placement was
similar among all racial/ethnic groups.
The analysis of MNC collected per liter of blood processed
found a signiﬁcant interaction between the main effect of
race and gender. The comparisons between Caucasians
versus other race groups are summarized in Figure 2. AA
male donors had better MNC per liter collection compared
with Caucasian male donors. No signiﬁcant differences in
MNC per liter were found between Caucasians and any other
race groups.
For product CD34þ cells to MNC ratio, there was no sig-
niﬁcant difference between Caucasian donors and NA do-
nors, whereas Hispanic, AA, and API donors all had greater
CD34þ to MNC ratios compared with Caucasian donors. No
signiﬁcant differences in CD34þ to MNCwere found between
the 4 minority race groups (data not shown).
A linear mixed model with a random effect for apheresis
center was used to assess the effect of donor race/ethnicity
on the changes in peripheral blood cell counts from baseline
to preapheresis, after adjusting for signiﬁcant effects among
donor gender, age, BMI, baseline CBC, and year of donation.
Caucasian donors had lower DWBC and DNeu counts
compared with AA, Hispanic, and API donors. Caucasian
donors also had lower changes in MNC compared with AA
and API donors (primarily among males). However, Cauca-
sian donors had greater DPlt compared with Hispanic and
API donors. No signiﬁcant differences in the changes in pe-
ripheral blood cell counts were found between Caucasian
donors and NA donors. For comparisons between the 4Table 3
Donor Response after Five Days of G-CSF
Variable Caucasian HIS
DWBC,  109/L 30.9 (1.7-97.4) 35.1 (1.7-83.3)
DPlt,  109/L 19 (280 to 211) 27 (210 to 228)
DNeu,  109/L 27.0 (.9 to 91.7) 30.3 (1.2-78.7)
DMNC,  109/L 3.4 (2.4 to 28.3) 4.1 (1.8 to 20.7)
CD34þ before apheresis,  109/L 78.3 (.3-2236) 89.7 (4.7-1117)
Data presented are median (range).minority race groups, AA donors were found to have greater
DWBC, DNeu, and DMNC counts compared with Hispanic,
API, and NA donors (primarily amongmales for MNC counts).
AA donors also had greater DPlt compared with Hispanic and
API donors. API donors had greater DWBC and DNeu counts
but lower DPlt compared with Hispanic donors. API donors
also had lower DPlt compared with NA donors (data not
shown).
DISCUSSION
This is the largest study investigating PBSC collection
outcomes in unrelated donors. Prior studies on factors
inﬂuencing PBSC collection in volunteer donors have pri-
marily focused on gender, age, and G-CSF dose/timing [4-7].
Several studies have been published on the effect of race/
ethnicity in related donors [9-11]. However, most are limited
by the number of patients, especially in the non-Caucasian
cohorts.
We found statistically signiﬁcant differences in baseline
counts among different ethnic groups, with AA having the
lowest baseline counts and Hispanic and NA having the
highest baselines. As far as mobilization response to G-CSF,
AA had the highest response, both in terms of CD34þ cells
collected per liter of blood processed and CD34þ cells per
MNC. This translates into a median CD34þ cell dose of
8.0  106 CD34þ cells/kg in Caucasians versus 9.9  106
CD34þ cells/kg in AA (using median apheresis volumes and
CD34þ cells collected per liter and a typical donor weight of
80 kg). This implies that the presence of a low baseline count
in a volunteer donor does not necessarily predict for failure
to collect adequate amounts of CD34þ cells.
We found the use of a CVC catheter had a negative effect
on the collection of CD34þ cells and this was consistent
among all racial/ethnic groups. The reasons are not clear, but
hematopoietic progenitor cells are known to adhere to both
plastic and stromal cell layers in culture [13] and this may
contribute to our observation. Timing of CVC catheter
placement may also have an effect on CD34þ cell collections.
Peak concentration of CD34þ cells occurs approximately 4 to
6 days after the start of G-CSF administration [6]. CVC cath-
eters for volunteer donors are typically placed just before the
start of the ﬁrst day of apheresis. This delays the start of
apheresis by several hours and may miss the peak concen-
tration of circulating CD34þ cells, resulting in a lower CD34þ
collection yield.
Interestingly, differences in mobilization yields among
the ethnic groups appeared to bemost prominent in males in
the higher BMI categories. However, this effect does not
appear to be related to total dose of G-CSF per kilogram. Even
though there was a higher percentage of obese AA donors
compared with Caucasian donors (46% versus 28%), the
median weight of Caucasian donors was higher than AA
donors in each BMI category (Table 2). A multivariate model,
which included total dose of G-CSF/kg as a covariate in
addition to BMI, age, gender, and year of apheresis, found noAA API NA P Value
38.7 (6.1-79.3) 35.9 (4.8-90.4) 33.5 (9.3-81.0) <.001
23 (290 to 120) 30 (162 to 155) 26 (115 to 57) <.001
33.6 (5.6-68.1) 31.8 (3.4-85.8) 28.4 (5.7-76.6) <.001
4.5 (.7 to 16.8) 3.7 (.7 to 21.5) 4.1 (.9 to 17.4) <.001
112 (3.4-1089) 87.3 (.3-1145) 79.5 (17.4-292) <.001
Table 4
Collection Efﬁciency after Day 1 of Apheresis
Variable Caucasian HIS AA API NA P Value
Total MNC,  109 50.7 (.6-177) 49.4 (4.2-184) 50.7 (6.9-161) 46.2 (4.1-123) 51.4 (19.7-235) <.001
MNC/L of blood processed,  109/L 2.8 (.1-13.1) 3.0 (.2-12.1) 3.1 (.6-9.3) 2.8 (.3-7.1) 3.1 (1.0-11.7) <.001
Total CD34þ,  106 616.2 (7.9-4677) 615.3 (54.2-3321) 704.0 (7.9-3985) 555.8 (72.4-2795) 651.3 (101.1-2986) <.001
CD34þ/L of blood processed,  106/L 33.6 (.4-285) 36.0 (3.1-151) 44.0 (.6-210) 34.6 (4.4-155) 36.8 (6.8-149) <.001
CD34þ/MNC,  103 11.9 (.1-430.0) 12.2 (1.1-230.0) 13.6 (.2-150.0) 12.5 (1.9-169.4) 11.8 (2.8-66.8) <.001
Data presented are median (range).
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yields (data not shown). These observations imply that the
difference in CD34þ cell collection yields is not due to G-CSF
dose.
These ﬁndings are consistent with information published
on studies of related PBSC donors. Carilli et al. reported, in a
small case control study of 22 AA and 12 Hispanic related
donors, signiﬁcantly lower baseline WBC and neutrophil
counts in AA donors compared with matched Caucasian
donors [10]. Despite these differences, they found no sig-
niﬁcant difference in product cell counts after G-CSF mobi-
lization. Richa et al. reported in a cohort of 195 consecutive
sibling PBSC donors (including 16 AA donors) a mean CD34þ
count of 102.5 cells/mL in AA compared with 84.7 cells/mL in
Caucasians, which was not statistically signiﬁcant (P ¼ .12)
[11]. A larger trial of 639 allogeneic PBSC donors by Vasu et al.
(including 75 AA donors) had similar ﬁndings [9]. In their
multivariate analysis, G-CSF dose was most strongly associ-
ated with day 5 CD34þ cell counts. However, donor ethnicity
was also found to be a statistically signiﬁcant risk factor, with
Caucasians associated with signiﬁcantly lower post-G-CSF
CD34þ cell counts.
The differences in baseline counts and response to G-CSF
suggest a potential impact of racially related genetic
polymorphisms in the G-CSF receptor and other proteins
involved with mobilization. The mechanism of action of
G-CSF mobilization has been previously reviewed [14]. G-CSF
is thought to produce alterations in the HPC niches, which
includes downregulation of adhesion proteins and chemo-
kines, such as vascular cell adhesion protein 1 (VCAM-1),
stromal cell-derived factor 1 (SDF-1), and stem cell factor
(SCF) [15,16]. Additionally, activation of the complement and
thrombolytic pathways by release of neutrophil proteases
may also contribute to mobilization by causing the release of
erythrocyte sphingosine-1-phosphate (a chemo-attractant)
into the plasma [17]. Genetic linkage analyses in mice have< .001
< .001
< .001
P =
Figure 1. Pairwise analysis of race by gender and BMI on CD34þ cells per liter of blo
adjusted for gender, age, BMI, and year of apheresis. Box indicates mean difference (identiﬁed several loci associated with poor mobilization
[18,19]. In humans, polymorphisms in the G-CSF receptor
that result in inferior mobilization responses and survivals in
the autologous setting have been identiﬁed [20]. Poly-
morphisms in SDF-1, VCAM-1 and CD44 have also been
identiﬁed [21,22]. A recent report, however, found no sig-
niﬁcant effect of SDF-1 polymorphism on the mobilization
efﬁciency in 467 healthy volunteer donors [23]. Currently,
there are no published systematic investigations of genetic
differences of these molecules among ethnic lines and
further research in this area is warranted.
Alterations in the HPC microenvironment can also result
in alteration in the ability to mobilize cells. Aging has been
associated with decreased osteoblastic activity and may
result in decreased niches for development of HPCs [24].
Parathyroid hormone has been shown to alter the conditions
of the stem cell niche through activation of osteoblasts and
can enhance stem cell collection [25]. This may partially
explain differences in mobilization responses, as increased
parathyroid hormone levels have been seen in AA males [26]
and in obese patients [27].
There are several limitations to this study. Classiﬁcation of
donors on race/ethnicity is self reported, which can cause
misclassiﬁcation of donors into the appropriate racial/ethnic
group if the donor’s recollection of their genealogy is
imperfect or erroneous. Although all donors underwent
rigorous screening before apheresis, information concerning
concomitant medications was not captured in this study.
Beta-adrenergic blocking agents have been shown to reduce
the ability to mobilize stem cells in a mouse model [28]. The
same report also showed use of a beta agonist increased the
number of circulating CD34þ cells. However, the signiﬁcance
of this ﬁnding in humans is not known.
Time of day of apheresis was not analyzed in our study.
There is a circadian rhythm in the production of SDF-1 in HPC
niche cells and C-X-C motif receptor 4 (CXCR4) expression inP =
< .001
od processed using measurements from Caucasian donors as baseline. Model
 106/L) with 95% conﬁdence interval. (L) for male and (R) for female.
< .001P =
Figure 2. Pairwise analysis of race by gender on MNC per liter of blood pro-
cessed using measurements from Caucasian donors as baseline. Model
adjusted for gender, age, and BMI. Box indicates mean difference ( 109/L)
with 95% conﬁdence interval.
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nerves [29]. In a report of 85 healthy donors by Lucas et al.,
for donors who were apheresed in the afternoon, when the
level of circulating catecholamines are at their lowest, there
was a statistically signiﬁcant higher average mobilization
yield (.55  .05 CD34þ cells/mL/kg) compared with donors
apheresed in the morning (.35  .02 CD34þ cells/mL/kg). The
effect was persistent, even when accounting for age and
gender of the donors [30].
Concomitant medical conditions in the donor may also
have an effect in the ability to mobilize stem cells. In a mouse
model, high cholesterol levels have been implicated to
enhance mobilization by disrupting the SDF-1/CXCR4 axis
[31]. A study by Crysandt et al. revealed improved mobili-
zation in patients with hypercholesterolemia in a cohort of
104 patients undergoing autologous apheresis in a mixed
disease population [32]. However, in the general population,
hypercholesterolemia is more prevalent in the Caucasian
groups compared with AA or Hispanic ethnicities [33].
In conclusion, these results show there are signiﬁcant
differences in both baseline CBC and in G-CSF response and
mobilization yields among different ethnicities and should
be taken into account when implementing standard mobi-
lization protocols. It is unclear why these differences exist;
however, it has not prevented the ability to mobilize and
collect adequate quantities of stem cells for transplantation
from all groups. Understanding the reasons for these differ-
ences may improve our ability to collect PBSC in volunteer
donors and develop alternative mobilization regimens for
potentially difﬁcult mobilizers.
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